» Articles » PMID: 31996495

Development of an Immunoassay Using Recombinant Outer Membrane Protein A and Flagellin for Diagnosis of Goats with Melioidosis

Overview
Journal J Vet Med Sci
Date 2020 Jan 31
PMID 31996495
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Among domestic animals, melioidosis is one of the most common diseases reported in goat, sheep, and swine. To evaluate the specific antibodies in goats with melioidosis, we developed a serology test using recombinant outer membrane protein A (OmpA) and flagellin (FliC) of Burkholderia pseudomallei as antigens. DNA corresponding to each antigen was cloned into a pET32a vector and expressed in Escherichia coli. Essentially, the recombinant OmpA and FliC were expressed in a soluble form that could be isolated with 95% homogeneity. Both recombinants could be recognized by rabbit antibodies prepared against heat-inactivated B. pseudomallei (1:1,000) on a Western blot. Subsequently, we demonstrated that both recombinants could capture the antibodies present in goat with naturally occurring melioidosis (optimized titer 1:40) while not cross-reacting with the serum samples of goats naturally infected by Corynebacterium pseudotuberculosis or Staphylococcus aureus. Finally, an enzyme-linked immunosorbent assay (ELISA) using 20 goat serum samples without melioidosis and 10 goat serum samples with melioidosis demonstrated that the infected group has significantly higher antibody titer levels than the normal group (P<0.001) when using either OmpA or FliC as an antigen. However, the sensitivity (100%) of the assay using OmpA was superior to that (90%) from using FliC. Serological tests that are commonly used often rely on antigens from crude cell extracts, which pose risks for laboratory-acquired infections and inconsistency in their preparation; however, use of recombinant OmpA is safe; it can potentially be used as a reagent in testing for goat melioidosis.

Citing Articles

Isolation of Burkholderia pseudomallei from a goat in New Caledonia: implications for animal and human health monitoring and serological tool comparison.

Desoutter A, Deshayes T, Vorimore F, Klotoe B, Durand B, Colot J BMC Vet Res. 2024; 20(1):114.

PMID: 38521903 PMC: 10960402. DOI: 10.1186/s12917-024-03957-5.


A clinical study on clinical features,manifestations and drug resistance of melioidosis.

Hui H, Sheng Y, Han X, Wang S, Zhang G, Wei X Pak J Med Sci. 2022; 38(8):2301-2306.

PMID: 36415241 PMC: 9676572. DOI: 10.12669/pjms.38.8.5506.

References
1.
Chantratita N, Wuthiekanun V, Thanwisai A, Limmathurotsakul D, Cheng A, Chierakul W . Accuracy of enzyme-linked immunosorbent assay using crude and purified antigens for serodiagnosis of melioidosis. Clin Vaccine Immunol. 2006; 14(1):110-3. PMC: 1797717. DOI: 10.1128/CVI.00289-06. View

2.
Limmathurotsakul D, Thammasart S, Warrasuth N, Thapanagulsak P, Jatapai A, Pengreungrojanachai V . Melioidosis in animals, Thailand, 2006-2010. Emerg Infect Dis. 2012; 18(2):325-7. PMC: 3310465. DOI: 10.3201/eid1802.111347. View

3.
Perumal Samy R, Stiles B, Sethi G, Lim L . Melioidosis: Clinical impact and public health threat in the tropics. PLoS Negl Trop Dis. 2017; 11(5):e0004738. PMC: 5426594. DOI: 10.1371/journal.pntd.0004738. View

4.
Lai I, Tsai T, Lin H, Lai W, Mao S . Cloning and expression of human haptoglobin subunits in Escherichia coli: delineation of a major antioxidant domain. Protein Expr Purif. 2006; 52(2):356-62. DOI: 10.1016/j.pep.2006.09.012. View

5.
Yang S . Melioidosis research in China. Acta Trop. 2000; 77(2):157-65. DOI: 10.1016/s0001-706x(00)00139-x. View